UPDATE: Qiagen Q2 Revenues Bounce 9 Percent; Plans to Buy Back $100M in Shares | GenomeWeb

The story has been updated to include comments from Qiagen's conference call.

NEW YORK (GenomeWeb News) – Qiagen reported after the close of the market on Tuesday that revenues increased 9 percent year over year as both instruments and consumables and related sales bounced in the double digits.

The company also announced its first share buyback program with plans to repurchase up to $100 million in Qiagen shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.